Pancreatic Cancer Research

ResearcherSoochow UniversityNo recent work listed

Min Tao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8129-145X; OpenAlex author ID A5101932267. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
58
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: 1 paper · 2015: 7 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper

Papers 19

  1. Author Correction: Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Co-author DOI 10.1038/s41598-021-84394-4↗
  2. FOLFIRINOX regulated tumor immune microenvironment to extend the survival of patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.21037/gs-20-828↗
  3. Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis. Last author DOI 10.1002/jcb.29253↗
  4. Inflammation Promotes Progression of Pancreatic Cancer Through WNT/β-Catenin Pathway-Dependent Manner. Co-author DOI 10.1097/mpa.0000000000001386↗
  5. The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer. Co-author DOI 10.1038/s41389-018-0102-2↗
  6. Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresect… Co-author DOI 10.18632/oncotarget.21340↗
  7. Inflammatory stimuli promote growth and invasion of pancreatic cancer cells through NF-κB pathway dependent repression of PP2Ac. Co-author DOI 10.1080/15384101.2015.1127468↗
  8. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis. Co-author DOI 10.18632/oncotarget.9975↗
  9. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… Co-author DOI 10.3892/ijo.2015.3316↗
  10. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s12032-014-0358-0↗
  11. Cantharidin represses invasion of pancreatic cancer cells through accelerated degradation of MMP2 mRNA. Co-author DOI 10.1038/srep11836↗
  12. Effect of Diabetes Mellitus on Survival in Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. First author DOI 10.1038/srep17102↗
  13. Diabetes Associated With Short Survival in Pancreatic Cancer. First author DOI 10.1200/jco.2014.60.2896↗
  14. FH535 inhibited metastasis and growth of pancreatic cancer cells. Last author DOI 10.2147/ott.s82718↗
  15. Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine an… Co-author DOI 10.3892/ijo.2015.3156↗
  16. Tamoxifen enhances the anticancer effect of cantharidin and norcantharidin in pancreatic cancer cell lines through inhibition of the protein kinase C signaling… Last author DOI 10.3892/ol.2014.2711↗
  17. PP2A inhibitors suppress migration and growth of PANC-1 pancreatic cancer cells through inhibition on the Wnt/β-catenin pathway by phosphorylation and degradat… Last author DOI 10.3892/or.2014.3266↗
  18. PP2A inhibitors induce apoptosis in pancreatic cancer cell line PANC-1 through persistent phosphorylation of IKKα and sustained activation of the NF-κB pathway. Co-author DOI 10.1016/j.canlet.2011.02.009↗
  19. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathwa… Co-author DOI 10.1016/j.ejca.2011.08.014↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Meng Shen · 9 shared papers, 2015–2021 · strength 0.67
  2. Qiaoming Zhi · 8 shared papers, 2015–2021 · strength 0.55
  3. Kai Chen · 8 shared papers, 2011–2021 · strength 0.51
  4. Mengyao Wu · 7 shared papers, 2015–2020 · strength 0.50
  5. Mengyao Wu · 5 shared papers, 2014–2021 · strength 0.32
  6. Mengdan Xu · 3 shared papers, 2018–2020 · strength 0.30
  7. Daoming Li · 5 shared papers, 2011–2021 · strength 0.29
  8. Wei Li · 4 shared papers, 2015–2018 · strength 0.23
  9. Wei Li · 2 shared papers, 2016–2021 · strength 0.18
  10. Yixiang Mao · 3 shared papers, 2015 · strength 0.17
  11. Weiming Duan · 4 shared papers, 2011–2016 · strength 0.17
  12. Lian Lian · 3 shared papers, 2015–2017 · strength 0.16
  13. Wei Li · 3 shared papers, 2014–2015 · strength 0.14
  14. Donghui Li · 2 shared papers, 2015 · strength 0.13
  15. Qing Chen · 1 shared paper, 2019 · strength 0.11
  16. Zekuan Xu · 3 shared papers, 2011–2014 · strength 0.09
  17. Zheng Chen · 3 shared papers, 2011–2014 · strength 0.09
  18. Xin Xie · 2 shared papers, 2014–2015 · strength 0.09
  19. Wei Li · 1 shared paper, 2019 · strength 0.08
  20. Rui Ren · 1 shared paper, 2019 · strength 0.08
  21. Xiaojie Bian · 1 shared paper, 2017 · strength 0.06
  22. Yuan Hong Gao · 1 shared paper, 2017 · strength 0.06
  23. Hongwei Tang · 1 shared paper, 2015 · strength 0.06
  24. Lu Liu · 1 shared paper, 2016 · strength 0.05
  25. Wenjie Wang · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.